|Mr. Stephan Sturm||CEO, Pres & Chairman of Management Board - Fresenius Management SE||3.49M||N/A||1963|
|Ms. Rachel Clare Empey||CFO & Member of Management Board - Fresenius Management SE||1.61M||N/A||1976|
|Dr. Francesco De Meo||Member of Management Board - Fresenius Management SE||2.4M||N/A||1963|
|Dr. Ernst Wastler||Member of Management Board - Fresenius Management SE||1.43M||N/A||1958|
|Mr. Mats Christer Henriksson||Member of Management Board - Fresenius Management SE||2.36M||N/A||1967|
Fresenius SE & Co. KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide. The company operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment offers dialyzers, hemodialysis machines, and related disposable products, as well as dialysis-related services. The Fresenius Kabi segment specializes in the therapy and care of chronically and critically ill patients. This segment offers IV drugs, including intravenously administered generic anesthetics, analgesics, anti-infectives, and drugs for the treatment of oncological and other critical diseases; parenteral and enteral nutrition products; infusion solutions and blood volume substitutes for infusion therapy; infusion and nutrition pumps, as well as consumables; and products that are used in the collection and processing of blood components, as well as in transfusion medicine and cell therapy. As of December 31, 2019, this segment operated 86 hospitals, approximately 125 outpatient clinics, and 8 prevention centers. The Fresenius Vamed segment manages projects and provides services for hospitals and other health care facilities. This segment offers project development, planning, and turnkey construction services, as well as maintenance, technical management, and operational management services. Fresenius SE & Co. KGaA has a strategic partnership with Humacyte Inc. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg vor der HÃ¶he, Germany.
Fresenius SE & Co. KGaA’s ISS governance QualityScore as of 8 December 2019 is 8. The pillar scores are Audit: 10; Board: 6; Shareholder rights: 1; Compensation: 8.